Modeling ErbB2-p130Cas interaction to design new potential anticancer agents-Reference-Cited by-同舟云学术

Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

Published:2019-02-28 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Costamagna Andrea,Rossi Sebastiano Matteo,Natalini Dora,Simoni Matilde,Valabrega Giorgio,Defilippi Paola,Visentin Sonja,Ermondi Giuseppe,Turco Emilia,Caron Giulia,Cabodi Sara^ORCID

Funder

University of Torino: Ex-60% Funding

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-39510-w.pdf

Reference39 articles.

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359–386 (2015).

2. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).

3. Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19, 6102–6114 (2000).

4. Appert-Collin, A., Hubert, P., Cremel, G. & Bennasroune, A. Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol 6, 283 (2015).

5. Bisaro, B. et al. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. Oncotarget 7, 4442–4453 (2016).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers;Journal of Advanced Research;2023-05

2. P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer;Cell Death & Disease;2022-09-10

3. p130Cas/BCAR1 and p140Cap/SRCIN1 Adaptors: The Yin Yang in Breast Cancer?;Frontiers in Cell and Developmental Biology;2021-10-11

4. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects;Investigational New Drugs;2020-06-13

5. Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents;Scientific Reports;2019-11-22